Asha Therapeutics presented exciting new data for their lead Parkinson's Disease therapeutic ASHA-091 in one of its secondary indications for the drug this past week at The 12th International Biomedical Research into ME Colloquium at the Wellcome Sanger Institute in the United Kingdom. "Targeting mitochondrial dynamics is a promising therapeutic avenue to treating post-viral illnesses including ME/CFS. ASHA-091 is the perfect compound to do just this and we are excited to continue developing it